Tuesday, November 30, 2021 7:40:14 AM
Our net tangible book value as of September 30, 2021 was approximately ($22,411,123) or ($0.02436) per share. Net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of common stock outstanding as of September 30, 2021. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by the Selling Stockholders, and the net tangible book value per share of common stock immediately after such issuances to the Selling Stockholders.
After giving effect to the issuance of 254,958,294 shares of our common stock to the other Selling Stockholders at the assumed sale prices ranging from $0.20 to $1.00 per share, and after deducting estimated offering expenses payable by us, our as adjusted net tangible book value as of September 30, 2021 would have been approximately $16,826,377, or $0.01423 per share.
SEC rule17(b) does not prohibit free speech. It does not prohibit spamming, online newsletters, posting on message boards, without other activity as well. But lying to investors, or failing to disclose compensation, does violate the law
Recent HMBL News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 02:19:41 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 01/03/2024 05:00:32 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/06/2023 09:05:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2023 01:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 09:20:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/31/2023 01:15:12 PM
- Form 1-A - Offering Statement [Regulation A] • Edgar (US Regulatory) • 08/22/2023 07:48:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:14:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:53:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:15:09 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 06/30/2023 08:35:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM